強気
$14.87
シナリオ価格
$11.110
-0.244 (-2.20%)終値時点
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
Alphatec Holdings Inc (ATEC) is a good buy right now due to its current price of $10.46, which is below the analyst price targets of $12 and $15. The company's gross margin has improved to 70.34% in Q2 2026, indicating strong profitability potential. Additionally, insider activity is bullish, with CEO Miles Patrick purchasing shares at $8.81, reflecting confidence in the company's future. However, the main risk is the negative earnings per share (EPS) of -0.16 reported in Q2 2026, which shows ongoing financial challenges.
BMO Capital
$12
2026-08-05
BMO Capital
2026-08-05
目標株価
$12
UBS
$15
2026-07-28
UBS
2026-07-28
目標株価
$15
Stephens
$15
2026-07-23
Stephens
2026-07-23
目標株価
$15
Stifel
$13
2026-07-08
Stifel
2026-07-08
目標株価
$13
Barclays
$24
2026-05-07
Barclays
2026-05-07
目標株価
$24
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

Alphatec to Report Q3 2026 Financial Results on October 29

Alphatec CEO's Stock Purchase Signals Confidence

Alphatec CEO's Stock Purchase Signals Confidence

ATEC Appoints New Executive to Advance Data Strategy

Alphatec (ATEC) Q2 2026 Earnings Call Transcript
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Alphatec Holdings Inc (ATEC) is a good buy right now due to its current price of $10.46, which is below the analyst price targets of $12 and $15. The company's gross margin has improved to 70.34% in Q2 2026, indicating strong profitability potential. Additionally, insider activity is bullish, with CEO Miles Patrick purchasing shares at $8.81, reflecting confidence in the company's future. However, the main risk is the negative earnings per share (EPS) of -0.16 reported in Q2 2026, which shows ongoing financial challenges.
3 analysts cover ATEC: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 24.33.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。